Literature DB >> 30635487

Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders.

Christiane E Whitehouse1, John D Fisk1, Charles N Bernstein1, Lindsay I Berrigan1, James M Bolton1, Lesley A Graff1, Carol A Hitchon1, James J Marriott1, Christine A Peschken1, Jitender Sareen1, John R Walker1, Sherry H Stewart1, Ruth Ann Marrie2.   

Abstract

OBJECTIVE: To determine whether anxiety and depression are associated with cognition in multiple sclerosis (MS), and whether these associations are similar in other immune-mediated inflammatory diseases (IMID; including inflammatory bowel disease [IBD] and rheumatoid arthritis [RA]) and in anxious/depressed individuals (ANX/DEP) without an IMID.
METHODS: Participants (MS: n = 255; IBD: n = 247; RA: n = 154; ANX/DEP: n = 308) completed a structured psychiatric interview, the Hospital Anxiety and Depression Scale, and cognitive testing, including the Symbol Digit Modalities Test, the California Verbal Learning Test, and Letter Number Sequencing test. Test scores were converted to age-, sex-, and education-adjusted z scores. We evaluated associations of anxiety and depression with the cognitive z scores using multivariate linear models, adjusting for disease cohort.
RESULTS: All cohorts exhibited higher rates of impairment (i.e., z less than or equal to -1.5) in the domains of processing speed, verbal learning, and delayed recall memory relative to general population norms. Higher levels of anxiety symptoms were associated with slower processing speed, lower verbal learning, and lower working memory performance (all p < 0.001); higher levels of depression symptoms were associated with slower processing speed. These associations did not differ across cohorts.
CONCLUSION: Anxiety and depression are associated with lower cognitive function in MS, with a similar pattern observed in persons with other IMID, including IBD and RA, and persons without an IMID. Managing symptoms of anxiety and of depression in MS, as well as other IMIDs, is important to mitigate their effect on cognition.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 30635487      PMCID: PMC6369907          DOI: 10.1212/WNL.0000000000006854

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.

Authors:  Rachel Brandstadter; Ilana Katz Sand; James F Sumowski
Journal:  Mult Scler       Date:  2019-09       Impact factor: 6.312

Review 2.  Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis.

Authors:  Diulle Spat Peres; Patrícia Rodrigues; Fernanda Tibolla Viero; Julia Maria Frare; Sabrina Qader Kudsi; Graziela Moro Meira; Gabriela Trevisan
Journal:  Brain Behav Immun Health       Date:  2022-07-06

3.  The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a.

Authors:  Hanne van Ballegooijen; Karin van der Hiele; Christian Enzinger; Gert de Voer; Leo H Visser
Journal:  eNeurologicalSci       Date:  2022-06-14

4.  Influence of Comorbidities on Healthcare Expenditures and Perceived Physical and Mental Health Status Among Adults with Multiple Sclerosis: A Propensity Score-Matched US National-Level Study.

Authors:  Sandipan Bhattacharjee; Zufan Yegezu; Kristin Kollecas; Kevin Duhrkopf; Lobat Hashemi; Nupur Greene
Journal:  Clinicoecon Outcomes Res       Date:  2021-05-13

5.  Sleep disturbance and memory dysfunction in early multiple sclerosis.

Authors:  James F Sumowski; Sam Horng; Rachel Brandstadter; Stephen Krieger; Victoria M Leavitt; Ilana Katz Sand; Michelle Fabian; Sylvia Klineova; Robin Graney; Claire S Riley; Fred D Lublin; Aaron E Miller; Andrew W Varga
Journal:  Ann Clin Transl Neurol       Date:  2021-05-05       Impact factor: 4.511

6.  Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis.

Authors:  Carol A Hitchon; Lixia Zhang; Christine A Peschken; Lisa M Lix; Lesley A Graff; John D Fisk; Scott B Patten; James Bolton; Jitender Sareen; Renée El-Gabalawy; James Marriott; Charles N Bernstein; Ruth Ann Marrie
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-07-08       Impact factor: 4.794

Review 7.  The Link Between Autonomic Nervous System and Rheumatoid Arthritis: From Bench to Bedside.

Authors:  Francesca Ingegnoli; Massimiliano Buoli; Flavia Antonucci; Lavinia Agra Coletto; Cecilia Maria Esposito; Roberto Caporali
Journal:  Front Med (Lausanne)       Date:  2020-12-07

8.  Neuroimmunology of depression.

Authors:  Erika Sarno; Adam J Moeser; Alfred J Robison
Journal:  Adv Pharmacol       Date:  2021-04-26

9.  Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.

Authors:  Ruth Ann Marrie; Ronak Patel; Charles N Bernstein; James M Bolton; Lesley A Graff; James J Marriott; Carol A Hitchon; Chase R Figley; Jennifer Kornelsen; John D Fisk
Journal:  Mult Scler       Date:  2020-09-25       Impact factor: 6.312

10.  The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients.

Authors:  Jose Luis Platero; María Cuerda-Ballester; Vanessa Ibáñez; David Sancho; María Mar Lopez-Rodríguez; Eraci Drehmer; Jose Enrique de la Rubia Ortí
Journal:  Nutrients       Date:  2020-01-23       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.